Allium Financial Advisors LLC Purchases Shares of 1,360 Eli Lilly and Company (NYSE:LLY)

Allium Financial Advisors LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent filing with the SEC. The fund purchased 1,360 shares of the company’s stock, valued at approximately $1,123,000. Eli Lilly and Company comprises about 1.0% of Allium Financial Advisors LLC’s portfolio, making the stock its 18th largest holding.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Garner Asset Management Corp grew its stake in shares of Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after buying an additional 12 shares in the last quarter. Applied Finance Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 1.4% during the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock worth $660,000 after purchasing an additional 12 shares during the period. Tobias Financial Advisors Inc. boosted its stake in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company’s stock worth $237,000 after purchasing an additional 12 shares during the period. Redwood Investments LLC boosted its stake in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Redwood Investments LLC now owns 2,209 shares of the company’s stock worth $1,705,000 after purchasing an additional 12 shares during the period. Finally, Hobbs Wealth Management LLC boosted its stake in shares of Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after purchasing an additional 12 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.8%

NYSE:LLY opened at $811.73 on Friday. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37. The firm has a market cap of $769.31 billion, a P/E ratio of 66.05, a P/E/G ratio of 1.16 and a beta of 0.40. The firm has a 50-day simple moving average of $771.95 and a 200-day simple moving average of $800.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The company’s revenue was up 45.2% compared to the same quarter last year. During the same quarter last year, the firm earned $2.58 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.74%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 48.82%.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an “overweight” rating and a $975.00 price target for the company. Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and dropped their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Morgan Stanley reiterated an “overweight” rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,012.56.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.